The obesity drug market is experiencing rapid expansion fueled by innovative GLP-1 therapies from leaders like Novo Nordisk and Eli Lilly. Projections indicate substantial growth to a $60 billion market by 2032, driven by new treatments offering efficacy comparable to bariatric surgery with fewer side effects.

In this report, Morningstar researchers examine two competing companies with obesity and their impact on the global obesity drug market.

Download the report to gain comprehensive insights into the booming obesity drug market and the future of obesity treatment.